Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

149
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
149
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

182
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
182

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reliability of Macular Ganglion Cell-Inner Plexiform Layer Thickness Measurements Across Scan Protocols in Spectral-Domain Optical Coherence Tomography.

Journal of clinical medicine·2026
Same author

The impact of age on efficacy and safety of disease modifying treatment-insights from the Austrian Multiple Sclerosis Treatment Registry.

Journal of neurology·2026
Same author

Integration of retinal layer thinning into NEDA-3 predicts disability progression in multiple sclerosis.

Journal of neurology·2026
Same author

Severe Immune-Related Neurological Adverse Events Associated With Immune Checkpoint Inhibitor Treatment: A Retrospective Single-Center Study.

European journal of neurology·2026
Same author

Idiopathic Intracranial Hypertension Is Characterized by a Distinct Proteomic Profile.

Annals of neurology·2026
Same author

Long-distance trail running induces functional iron deficiency driven by inflammation.

Blood advances·2026

Related Experiment Video

Updated: Jan 3, 2026

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
11:28

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques

Published on: March 13, 2015

41.4K

Serum hepcidin levels in multiple sclerosis.

Gabriel Bsteh1, David Haschka, Piotr Tymoszuk2

  • 1Department of Neurology, Medical University of Vienna, Austria.

Multiple Sclerosis Journal - Experimental, Translational and Clinical
|November 15, 2019
PubMed
Summary
This summary is machine-generated.

Serum hepcidin levels, a key regulator of iron, were investigated in multiple sclerosis (MS). This study found no association between hepcidin levels and MS disease activity or its progression.

Keywords:
Multiple sclerosisactivebiomarkerhepcidinironprogressive

More Related Videos

Induction of an Inflammatory Response in Primary Hepatocyte Cultures from Mice
08:32

Induction of an Inflammatory Response in Primary Hepatocyte Cultures from Mice

Published on: March 10, 2017

10.4K
Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools
07:01

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools

Published on: August 19, 2025

716

Related Experiment Videos

Last Updated: Jan 3, 2026

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques
11:28

Dried Blood Spots - Preparing and Processing for Use in Immunoassays and in Molecular Techniques

Published on: March 13, 2015

41.4K
Induction of an Inflammatory Response in Primary Hepatocyte Cultures from Mice
08:32

Induction of an Inflammatory Response in Primary Hepatocyte Cultures from Mice

Published on: March 10, 2017

10.4K
Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools
07:01

Navigating the Mass Spectrometry-Based Proteomic Data Using Free Computational Tools

Published on: August 19, 2025

716

Area of Science:

  • Neuroimmunology
  • Iron Homeostasis
  • Biomarker Discovery

Background:

  • Brain iron accumulation is linked to multiple sclerosis (MS).
  • Hepcidin regulates iron homeostasis but its role in MS is unknown.
  • Hepcidin dysregulation is seen in other chronic inflammatory conditions.

Purpose of the Study:

  • To measure serum hepcidin levels in MS patients and healthy controls.
  • To explore correlations between hepcidin levels, MS disease activity, and disease course.

Main Methods:

  • Cross-sectional study of 71 MS patients and 16 healthy controls (HC).
  • Serum hepcidin levels measured using standard laboratory methods.
  • MS patients categorized into active/inactive relapsing-remitting and progressive subtypes.

Main Results:

  • MS patients exhibited higher median hepcidin levels (26.9 ng/ml) compared to HC (17.3 ng/ml).
  • Hepcidin levels showed correlations consistent with its role as an iron store indicator.
  • After adjusting for age and sex, hepcidin levels were not associated with MS subgroups, disability, or relapse rates.

Conclusions:

  • Serum hepcidin levels do not correlate with disease activity in multiple sclerosis.
  • Hepcidin levels are not associated with the disease course or progression in MS patients.